Pulsed Field Ablation for Atrial Fibrillation in Obesity: Reassessing Risk, Safety, and Success
Journal of Clinical Medicine · 27.07.2026 · 15 (15) · 5866
DOI: 10.3390/jcm15155866 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.07.2026. Verfasst von Ridwan R Waliyuddin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta 11420, Indonesia. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Obesity is a major independent risk factor for atrial fibrillation (AF), contributing to adverse outcomes and complicating rhythm control. While lifestyle modification is recommended, catheter ablation remains central to management. Conventional thermal ablation techniques often yield suboptimal results in obese patients due to anatomical and biophysical challenges. Pulsed field ablation (PFA), a novel non-thermal modality, may overcome these limitations.
Methods
A systematic search of PubMed, Scopus, and Embase identified observational cohort studies (2017–2026) evaluating PFA outcomes in obese AF patients or across BMI categories. Four cohort studies met the inclusion criteria.
Results
Findings on AF recurrence were heterogeneous. Recurrence rates appeared lower with PFA compared to radiofrequency ablation (RFA), though differences were not statistically significant. In a PFA-only study, freedom from arrhythmia recurrence did not vary across BMI categories. Compared with cryoballoon ablation (CBA), one matched-cohort study demonstrated significantly higher one-year freedom from AF with PFA-PVI, whereas another reported no difference. Left atrial epicardial adipose tissue (LA EAT) emerged as the only independent predictor of recurrence in PFA patients, suggesting electrical field perturbation by fat tissue. Radiation exposure was lower with PFA than CBA, while fluoroscopy time and periprocedural complications were comparable across groups.
Conclusions
Current observational evidence suggests that PFA may be a feasible and safe option for AF ablation in overweight and obese patients, with outcomes comparable to conventional ablation techniques. However, comparative efficacy and long-term safety remain uncertain. Obesity-related adipose hypertrophy, systemic inflammation, and atrial remodeling may alter electric field distribution, contributing to variable recurrence outcomes. Larger prospective and randomized trials are warranted to define the long-term role of PFA in this high-risk population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta 11420, Indonesia.
- National Cardiovascular Center Harapan Kita, Jakarta 11420, Indonesia.
ORCID-Profile: Sunu B Raharjo, Dicky A Hanafy, Yoga Yuniadi
Zitieren
APA
Waliyuddin, R. R., Hermanto, D. Y., Raharjo, S. B., Hanafy, D. A., & Yuniadi, Y. (2026). Pulsed Field Ablation for Atrial Fibrillation in Obesity: Reassessing Risk, Safety, and Success. Journal of Clinical Medicine, 15(15), 5866. https://doi.org/10.3390/jcm15155866
Vancouver
Waliyuddin RR, Hermanto DY, Raharjo SB, Hanafy DA, Yuniadi Y. Pulsed Field Ablation for Atrial Fibrillation in Obesity: Reassessing Risk, Safety, and Success. Journal of Clinical Medicine. 2026;15(15):5866. doi:10.3390/jcm15155866
BibTeX
@article{Waliyuddin2026,
author = {Waliyuddin, Ridwan R and Hermanto, Dony Y and Raharjo, Sunu B and Hanafy, Dicky A and Yuniadi, Yoga},
title = {Pulsed Field Ablation for Atrial Fibrillation in Obesity: Reassessing Risk, Safety, and Success},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {15},
pages = {5866},
doi = {10.3390/jcm15155866}
}
EUVIMED